Daiichi Sankyo and MSD have announced the first subject dosing in the Phase III Ideate-Esophageal01 trial, assessing the safety and efficacy of ifinatamab deruxtecan (I-DXd) in individuals with ...

“This year’s ASCO marks the fourth in a row where potential practice-changing ENHERTU data will be showcased,” said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. “With the results ...

In addition, AstraZeneca, Daiichi Sankyo, and the pan-Canadian Pharmaceutical Alliance (pCPA) have signed a Letter of Intent under the Temporary Access Process (pTAP). Together with the TLR ...

NTK had filed a claim in October 2023, seeking damages of 20 billion yen from Daiichi Sankyo for allegedly obstructing its efforts to complete its open offers to acquire shares in Indian hospital ...

IHH Healthcare, supported by Mitsui, has increased its compensation claim against Daiichi Sankyo to $1.3 billion in the Tokyo District Court, related to the Fortis Healthcare acquisition.

IHH Healthcare Berhad’s indirect subsidiary Northern TK Venture Pte (NTK) has filed an application with the Tokyo District Court to increase its damages claim against Daiichi Sankyo Company by ...

New Delhi: Malaysia's IHH Healthcare is seeking JPY 200 billion (Rs 11,800 crore) in damages from Japan's Daiichi Sankyo for blocking its bid for control of Indian hospital operator Fortis.

(Image/Reuters) Northern TK Venture (NTK), a Singapore-based indirect arm of Malaysia’s IHH Healthcare, has raised its damages claims against Japanese pharma firm Daiichi Sankyo Company by ...

Merck MRK and Japan’s Daiichi Sankyo announced the dosing of the first patient in the phase III IDeate-Esophageal01 study evaluating their B7-H3 directed DXd antibody-drug conjugate (ADC ...

Northern TK Venture Pte Ltd. (NTK), a Singapore-based indirect subsidiary of IHH Healthcare Berhad, has sharply escalated its legal claim against Japan’s Daiichi Sankyo Co. Ltd., seeking damages ...